 Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the final data analysis from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease NAFLD with or without non-alcoholic steatohepatitis NASH has been completed. As a whole, the data show that Namodenoson at the 25 mg dose produced statistically significant results in all measures of efficacy, while also having a strong safety profile and well tolerated. 